04:30:48 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-19 Årsstämma 2024
2024-04-19 Ordinarie utdelning CLINE B 0.00 SEK
2024-02-23 Bokslutskommuniké 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-04-20 Ordinarie utdelning CLINE B 0.00 SEK
2023-04-19 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2023-02-17 Bokslutskommuniké 2022
2022-08-26 Kvartalsrapport 2022-Q2
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Ordinarie utdelning CLINE B 0.00 SEK
2022-04-20 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-08-27 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning CLINE B 0.00 SEK
2021-06-03 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-08-25 Kvartalsrapport 2020-Q2
2020-02-27 Ordinarie utdelning CLINE B 0.00 SEK
2020-02-26 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-05-08 Ordinarie utdelning CLINE B 0.00 SEK
2019-05-07 Årsstämma 2019
2019-02-22 Bokslutskommuniké 2018
2018-08-10 Kvartalsrapport 2018-Q2
2018-05-03 Ordinarie utdelning CLINE B 0.00 SEK
2018-05-02 Årsstämma 2018
2018-02-23 Bokslutskommuniké 2017
2017-08-11 Kvartalsrapport 2017-Q2
2017-03-21 Ordinarie utdelning CLINE B 0.00 SEK
2017-03-20 Årsstämma 2017
2017-02-17 Bokslutskommuniké 2016
2016-11-04 Kvartalsrapport 2016-Q3
2016-08-04 Kvartalsrapport 2016-Q2
2016-05-04 Ordinarie utdelning CLINE B 0.00 SEK
2016-05-03 Kvartalsrapport 2016-Q1
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-06 Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Cline Scientific är verksamt inom bioteknik. Bolaget är specialiserat inom cancerdiagnostik och stamcellsterapier. Bolaget genomför utvecklingsprojekt via samarbeten med forskningsinstitutioner, där teknologin används i cellbaserade produkter och processer för att driva Life Science projekt till och genom den kliniska fasen. Bolaget har sitt huvudkontor i Göteborg och grundades under 2012.
2021-12-07 13:00:00

Cline Scientific announces that they have appointed Professor and Orthopedic Surgeon Mats Brittberg as a new advisor for the company's StemCART project. 

Professor Mats Brittberg is currently a member of the Cartilage Research Unit, within the Department of Orthopedics Surgery, at the University of Gothenburg and an orthopedic surgeon at the Kungsbacka Hospital, Sweden. Mats Brittberg's research has been focused on cartilage repair and with the main focus on cartilage regeneration with autologous chondrocytes. Mats Brittberg has been on the board of TESI (Tissue engineering Society International) and has been the chair of the Cartilage Committee of ESSKA 2006-08. Since 1997, he has worked with ICRS (International Cartilage Regeneration and Joint Repair Society), as Secretary, Vice-president and President (2006-2008), and Past-President (2008-2009). Since January 2013, he has been the Editor-in-Chief of the journal CARTILAGE. He has received several accolades including ICRS Genzyme Lifetime Achievement Award in cartilage research, the United Kingdom Cartilage Club and Shetty-Kim Research Foundation's scientific Award, Canterbury Christ Church University, and UK Cartilage Club's Lifetime award in cartilage research.  He has also recently received the Lifetime Achievement award from Joint Preservation Congress in Warsaw, Poland.

In collaborating with Professor Brittberg, Cline will gain access to a wealth of experience within the area of cartilage repair, joint preservation, and tissue engineering. Professor Brittberg has been a pioneering figure in developing in vitro expanded autologous chondrocytes implantation and leading research collaborations around the world. Furthermore, his extensive experience as a prominent surgeon in this area will be a great asset as Cline continues their journey to bringing StemCART into clinical trials. 

"We are both honored and excited with the addition of Mats Brittberg to our StemCART team. The wealth of knowledge and experience he can bring to the project in both scientific and clinical aspect is certainly invaluable. We warmly welcome Professor Brittberg to join the journey with the StemCART venture!" Says Patrik Sundh, Cline Scientific CEO.

"It is very stimulating to have the opportunity to work with the Cline team on developing new repair methods how to control and guide stem- and progenitor cells into the chondrogenic pathway" Says Professor Mats Brittberg. 
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com 
Phone: +46 0703585088